Breaking News
1. Northeast to be gateway for trade with Southeast Asia: Modi      2. Will not be silenced by terrorism: Shashi Tharoor as his delegation heads to US      3. From nuclear blackmail to terror, Jaishankar delivers three messages on Pakistan      4. Pak's decades of terror, Pahalgam last straw: India on Indus treaty move at UN      5. "I Wear My Colours": Raghav Chadha Backs Harvard After Trump's Foreign Students Ban      6. After Shashi Tharoor, Anand Sharma hails Centre's anti-terror delegation as Congress criticises move      7. Supreme Court stays release of IAF officer with role in Operation Sindoor      8. 'Ties are built on basis of sensitivities to each other’s concerns': India's strong message to Turkey, China for backing Pakistan      9. 'Beautiful couple': Israeli Embassy staffers killed in US were soon to be engaged      10. Month after terror attack, Pahalgam tourist spots remain silent      11. What Harvard Said On Trump Halting Its Ability To Enroll Foreign Students      12. National Herald: Key questions raised by Delhi court on ED probe against Sonia Gandhi, Rahul Gandhi      13. Delhi rains: 2 killed, at least 11 injured; airport sees 13 flight diversions      14. ISI spy ring planning a terror strike in Delhi dismantled, 2 in custody      15. Nambala Keshav Rao aka Basavaraju, top Maoist leader killed in Bastar Op      16. Encounter In J&K's Kishtwar, Terrorists Trapped After Army Ops      17. No air defence guns deployed in Golden Temple during Op Sindoor, says Army      18. 'Critically hurt', co-founder of LeT Amir Hamza lands in Lahore hospital      19. Heavy rainfall likely in Mumbai, Bengal today; IMD predicts showers for Delhi: Weather updates      20. 'Golden Dome' Plan Unveiled: US To Get Cutting-Edge Missile Defence Shield     

Breakthrough Chikungunya Vaccine Approved by USFDA, Offers Vital Protection Against Global Threat

In a significant stride in global healthcare, the US Food and Drug Administration (USFDA) has granted approval to Ixchiq, marking the world's first-ever vaccine designed to prevent chikungunya virus-related diseases. Tailored for individuals aged 18 and above with heightened susceptibility to chikungunya exposure, Ixchiq stands as a crucial response to the escalating threat posed by this virus.

Breakthrough Chikungunya Vaccine Approved by USFDA, Offers Vital Protection Against Global Threat Image Source -www.hindi.news24online.com

Chikungunya, a mosquito-borne virus, has burgeoned into a global health concern, with over 5 million reported cases in the past 15 years. While traditionally associated with tropical regions in Africa, Southeast Asia, and the Americas, its geographical reach has expanded, amplifying the prevalence of the disease worldwide.

Common symptoms of chikungunya encompass fever, joint pain, rash, headache, and muscle pain. In severe cases, the joint pain can persist for months or even years, particularly affecting older adults and those with underlying health conditions.

Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research, emphasized the vaccine's approval as a crucial step in addressing an unmet medical need and providing a vital tool against a potentially debilitating disease.

Ixchiq, administered as a single muscle injection, contains a weakened form of the live chikungunya virus. Clinical studies in North America involving over 3,500 participants demonstrated the vaccine's safety, with common side effects being headache, fatigue, muscle and joint pain, fever, nausea, and injection site tenderness.

Despite rare severe reactions reported in 1.6% of Ixchiq recipients, the benefits of the vaccine outweigh the potential risks. The FDA mandates a postmarketing study to further assess these risks.

Transmission of the chikungunya virus to newborns has been documented, making Ixchiq's approval a significant development in safeguarding vulnerable populations. While the vaccine virus was detected in the blood shortly after vaccination, its impact on pregnant individuals and newborns remains uncertain.

Also Read: Tragic Loss In The Music World: South Korean Singer Nahee's Sudden Demise Stuns The Music Community

Ixchiq's approval comes under the Accelerated Approval pathway, reflecting the urgency in addressing the serious and life-threatening nature of chikungunya. Fast Track and Breakthrough Therapy designations, along with Priority Review, underscore the vaccine's significance in combating this global health menace.

Valneva Austria GmbH, the manufacturer, received a tropical disease priority review voucher as an incentive for advancing medical solutions targeting certain tropical diseases. This monumental approval represents a paradigm shift in combating chikungunya, offering hope and protection on a global scale. 

Author
No Image
Author
Arijit Dutta

You May Also Like